Close Menu

QuantumDx

John Burn has been appointed as a non-executive director of NHS England, QuantuMDx said this week.

NEW YORK (GenomeWeb) — QuantuMDx will use the proceeds from a recent financing round to optimize its handheld Q-POC molecular diagnostic device as well as several assays ahead of planned launches in 2015 and 2016.

NEW YORK (GenomeWeb News) – British molecular diagnostics company QuantuMDx has closed an $8.4 million investment round to further the development of a device for point-of-care testing, the firm said today.

NEW YORK (GenomeWeb News) – The Singapore Institute of Manufacturing Technology announced today a deal with QuantuMDx in support of the UK firm's development of a handheld point-of-care molecular diagnostic device.

NEW YORK (GenomeWeb News) – After years in development, a handheld point-of-care molecular diagnostic device from QuantuMDx is poised to hit the market next year with malaria and tuberculosis as its initial target markets, a company executive said last week on the sidelines of the 32nd Annual JP

QuantumDx CEO Elaine Warburton is being recognized for her work in the molecular diagnostics field and being dubbed an Officer of the Order of the British Empire.

QuantumDx CEO Elaine Warburton will become an Officer of the Order of the British Empire, the Newcastle, UK-based molecular diagnostics firm announced recently.

QuantumDx CEO Elaine Warburton will become an Officer of the Order of the British Empire, the Newcastle, UK-based molecular diagnostics firm announced recently.

NEW YORK (GenomeWeb News) – QuantuMDx said today that its subsidiary NorthGene has received accreditation from the UK's Ministry of Justice to perform legal DNA tests for parentage.

This story has been updated to clarify that QuantumDx has not yet invested in Pastel Bioscience.
UK-based biotech firm Pastel BioScience is building an array-based proteomics platform with the aim of accessing the entire human proteome.

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.